Zealand Pharma revenue and financials
kr 246.90Change from previous close: −1.67%Absolute change: −kr 4.20
In the fiscal year ended December 2025, Zealand Pharma reported revenue of kr 9.21B (+14,598.86% year over year). Net income was kr 6.46B, a net margin of 70.0%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14,598.86%
- 2025 vs 2024
- Net margin
- 70.0%
- 2024: -1,720.9%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 15,949 | 9,506 | 1,980 | 1,540 | — |
| Current assets | 15,670 | 8,528 | 1,780 | 1,316 | — |
| Cash and equivalents | 4,577 | 726 | 449 | 1,069 | — |
| Short-term investments | 10,532 | 7,500 | 1,184 | 109 | — |
| Receivables | — | — | — | — | 110 |
| Inventory | 0.0 | 10.7 | 7.9 | 1.3 | — |
| Net property, plant and equipment | 151 | 125 | 150 | 165 | — |
| Other intangible assets | 45.0 | 12.6 | 12.3 | — | 53.8 |
| Long-term investments | — | — | — | — | 26.9 |
| Current liabilities | 665 | 403 | 285 | 195 | — |
| Accounts payable | 257 | 181 | 91.6 | 181 | — |
| Long-term debt | 303 | 285 | 0.0 | 321 | — |
| Total debt | 406 | 392 | 119 | 443 | — |
| Total liabilities | 1,118 | 889 | 387 | 724 | — |
| Total equity (incl. minority) | 14,831 | 8,617 | 1,593 | 816 | — |
| Retained earnings | 6.3 | -6,157 | -4,895 | -4,172 | — |